Emd Serono Research & Development Institute, Inc.

This study tested whether adding tepotinib to osimertinib can help people with advanced non-small cell lung cancer whose cancer has a specific genetic change (MET amplification) and has stopped responding to osimertinib alone. About 140 participants received the combination thera…

This early-phase study tests a new drug called tuvusertib combined with other cancer treatments in people with advanced solid tumors that have stopped responding to standard therapy. The main goals are to find safe doses and understand side effects. About 120 adults with various …

This early-phase study tests a new drug called M9466, alone or with other treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goal is to check safety and how the drug moves through the body. About 141 participants will receive th…

This study tested the drug tepotinib in 337 adults with advanced lung cancer that has specific changes in the MET gene. The goal was to see if the drug could shrink or stop the growth of tumors. Participants took tepotinib pills, and researchers measured how many people had their…

This study tests whether combining avelumab with other anti-cancer drugs can help keep advanced bladder cancer from growing after initial chemotherapy. About 256 adults whose cancer did not worsen on first-line platinum chemo will receive one of several combination treatments. Th…

This early-phase study tests a new drug called tuvusertib, given alone or with another drug (niraparib), in people with advanced solid tumors that no longer respond to standard therapies. The main goals are to check safety, find the right dose, and see if the drug can shrink tumo…

This study tests a new combination of two drugs (tuvusertib and cemiplimab) in people with a type of advanced lung cancer that has stopped responding to standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors or slow the ca…

This study tests two new drug combinations for people with a type of ovarian cancer that has stopped responding to a standard treatment called PARP inhibitors. The trial involves 63 participants and aims to see if the new combinations can shrink or control the tumor. The goal is …

This early-stage study tests two drugs, avelumab and lenvatinib, together in children with certain types of brain tumors. The goal is to find safe doses and see if the combination can slow tumor growth. The study involves 17 children whose tumors have worsened after prior treatme…

This study follows people with solid tumors who are already taking the cancer drug avelumab to see how safe it is over a longer time. About 205 participants continue their same treatment or are monitored after finishing. Researchers track side effects, survival, and how well the …